Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY).
Astellas Pharma’s Bladder Cancer Treatment Scores Approval In Japan
Japan’s Ministry of Health, Labor, and Welfare (MHLW) has approved Astellas Pharma Inc’s (OTC: ALPMF) Padcev (enfortumab vedotin) for radically unresectable urothelial carcinoma…
Astellas’ Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Astellas Pharma Inc (OTC:ALPMF) has seen the fourth death in its experimental gene therapy trial gained through a $3 billion buyout…
After FDA Rejection, EMA Approves FibroGen-Astellas’ Roxadustat
The European Commission (EC) has approved FibroGen Inc (NASDAQ:FGEN) and Astellas Pharma’s (OTC:ALPMF) Evrenzo (roxadustat) for anemia caused by chronic kidney disease (CKD),…
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc’s (NASDAQ:FGEN) roxadustat for anemia of…
Analysts See Higher Success Chances For Cytokinetics’ Heart Disease Candidate After Positive Phase 2 Data
Today, Cytokinetics Incorporated (NASDAQ: CYTK) reported positive REDWOOD-HCM Phase 2 data showing CK-274 treatment for ten weeks
Astellas – Seagen’s PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ:SGEN) – Astellas Pharma Inc’s (OTC:ALPMF) PADCEV to treat patients with advanced or…
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTC:ALPMY) is walking away from a pact to research and develop…